Xylem’s New Smart Wastewater Treatment Solution Cuts Operating Costs and Reduces Energy Use by 25%
Wastewater utilities can now achieve compliance targets while cutting energy consumption from aeration by up to 25% with Xylem Edge Control. This off-the-shelf suite of digital solutions for conventional activated sludge (CAS) plants marks the latest breakthrough in the digitization of water utilities. With Xylem Edge Control, wastewater operators can now control and monitor their assets, improve nutrient removal, save energy and reduce costs.
“Wastewater utilities are constantly balancing the need to ensure service reliability and compliance alongside the need to manage costs,” said Chris Taylor, Global Product Manager at Xylem. “Xylem Edge Control helps wastewater utilities confidently walk that line, bringing together our digital innovation expertise and insights from our deep bioprocessing experience, in a suite of solutions that maximizes process control while dramatically cutting energy consumption and supporting sustainability goals.”
“Utilities around the world are well on the way to digitizing their networks and reaping major water, energy and cost efficiencies. Xylem Edge Control is a versatile, multi-functional solution that meets wastewater utilities where they are on that journey – and sets them up to unlock more of the benefits of digital transformation.”
The Edge Control solutions apply analytics to real-time data to provide rapid process recommendations to optimize chemical usage and aeration. As utilities target emissions reductions, Edge Control is the latest high-efficiency technology that can help utilities cut energy-related greenhouse gas (GHG) emissions and make fast progress towards achieving net-zero targets. The platform can operate with any Programmable Logic Controller under various communications protocols and connect to existing hardware, including sensors and probes.
Xylem Edge Control combines four solutions:
- Xylem Edge Control Pulsed Aeration: A digital, energy saving solution that can prevent over-aeration of underloaded treatment plants. Pulsed Aeration improves the overall biological process of CAS plants, to provide adequate mixing and ultimately achieving energy savings. Research and implementation of Pulsed Aeration has shown energy savings of approximately 25% can be achieved.
- Xylem Edge Control Ammonia Removal: Xylem Edge Control Ammonia Removal determines a CAS facility's ammonia target and helps meet its nutrient discharge limits while working to maximize energy savings. It uses an advanced algorithm to match various load conditions, that can provide consistent ammonia removal and further stabilize the biological process.
- Xylem Edge Control Ammonia + Nitrogen Removal: The solution offers wastewater utilities the potential to save energy while reducing nitrate and ammonia concentrations. It uses an advanced algorithm which communicates with CAS facilities’ existing assets to optimize the achievement of nutrient compliance targets. Its patented, one-of-a-kind, AvN® wastewater treatment process1 has the ability to create a biological environment unlike anything the wastewater treatment industry has seen with its capacity to create a Nitrite shunt. This can allow for an expedited denitrification process and ultimately, increased energy savings. Research and implementation of Ammonia + Nitrogen Removal has shown energy savings of approximately 25% in addition to a reduction in Total Inorganic Nitrogen (TIN) concentration of approximately 30%.
- Xylem Edge Control P - Removal: This solution controls chemical feed pumps based on real-time phosphorus concentrations to reduce chemical usage while meeting today’s stricter phosphorus limits.
The launch of Xylem Edge Control follows rigorous field testing across North America, including Washington and Indiana, including the wastewater treatment operations serving the city of Muncie, Indiana.
“With Muncie being the home to Ball State University, the city undergoes a major swing in population from around 70,000 people while school is in session to approximately 48,000 when school is out of session,” said Jason Ingram, Plant Superintendent at Muncie Wastewater Treatment Plant in Muncie, IN, where Xylem Edge Control Pulsed Aeration has been installed. “That’s a decrease in population of over 30%. It is during these months of decreased load where we benefit from Pulsed Aeration most. With our upgrades from Xylem’s Pulsed Aeration we are able to save $5,000 a month on energy costs.”
Global water utilities account for approximately 2% of global GHG emissions – the equivalent of the world’s shipping industry. However, innovative solutions like Edge Control can help mitigate a substantial portion of the emissions generated by inefficient wastewater operations, quickly and affordably. Furthermore, by deploying readily available advanced solutions, utilities could cut the water industry’s GHG emissions by 50% across both clean water and wastewater activities.
Xylem Edge Control can be used as a stand-alone process or as a connected, subscription-based enterprise with fees based on efficiency and savings. When connected via the Cloud, Xylem Edge Control provides data visualization, allowing the customer to see the energy savings on a monthly basis; real-time data trending reports, showing details such as ammonia and TIN concentrations and alert and alarm texts/email notifications, displaying instrumentation and software status.
Xylem Edge Control Pulsed Aeration, Xylem Edge Control Ammonia Removal and Xylem Edge Control Ammonia + Nitrogen Removal are now available for purchase globally. Xylem Edge Control P – Removal will be available to customers globally later this year.
About Xylem
Xylem (XYL) is a leading global water technology company committed to solving critical water and infrastructure challenges with innovation. Our 17,000 diverse employees delivered revenue of $5.2 billion in 2021. We are creating a more sustainable world by enabling our customers to optimize water and resource management, and helping communities in more than 150 countries become water-secure. Join us at www.xylem.com.
________________________
1 AvN® is a trademark of World Water Works, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220407005488/en/
Contact information
Media
Houston Spencer
+1.914.240.3046
Houston.Spencer@xylem.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 10:05:00 EET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge ® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 10:00:00 EET | Press release
Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support commercial manufacturing of Omisirge® for this additional indication at its state-of-the-art cGMP cell therapy manufacturing facility in Hopkinton, MA. “We are excited to expand our collaboration with RoslinCT to add US manufacturing as Omisirge® moves into its next phase with the recent FDA approval for patients suffering from severe apl
Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 08:00:00 EET | Press release
Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It proves a supplier has undergone an exhaustive audit of its governance, security controls, and operational processes. For Dutch financial institutions, this qualificatio
Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 04:00:00 EET | Press release
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform16.12.2025 03:00:00 EET | Press release
Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies per Shine-On’s instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. ShineOn’s proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review and ongoing Phase I study, making it as a first-in-class–potential HLA-G targeted exosome platfo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom